Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - INVO Bioscience, Inc. | ex_121483.htm |
| EX-31.1 - EXHIBIT 31.1 - INVO Bioscience, Inc. | ex_121482.htm |
| 10-Q - FORM 10-Q - INVO Bioscience, Inc. | invobio20180630_10q.htm |
EXHIBIT 32
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of INVO Bioscience, Inc. (the “Company”) for the period ended June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Kathleen Karloff, Chief and Principal Executive Officer of the Company, and Robert J Bowdring, Acting Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
INVO BIOSCIENCE |
|
|
|
|
|
|
|
|
Date: August 14, 2018 |
By: |
/s/ Kathleen Karloff |
|
|
|
|
Kathleen Karloff |
|
|
|
|
Chief Executive Officer |
|
|
|
|
|
|
|
|
INVO BIOSCIENCE |
|
|
|
|
|
|
|
|
Date: August 14, 2018 |
By: |
/s/ Robert J. Bowdring |
|
|
|
|
Robert J. Bowdring |
|
|
|
|
Acting Chief Financial Officer |
|
|
|
|
|
|